A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
This randomized phase III trial studies ipilimumab to see how well it works compared to
high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that
has been removed by surgery. Monoclonal antibodies, such as ipilimumab, can block tumor
growth in different ways. Some block the ability of tumor cells to grow and spread. Others
find tumor cells and help kill them or carry tumor-killing substances to them. Interferon
alfa-2b may interfere with the growth of tumor cells and slow the growth of melanoma and
other cancers. It is not yet known whether ipilimumab is more effective than interferon
alfa-2b in treating patients with melanoma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.